PATIENT INFORMATION LEAFLET

Similar documents
PATIENT INFORMATION LEAFLET. PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM LUMIGAN 0,01 %, bimatoprost 0,1 mg/ml eye drops

Package Leaflet: Information for the user. LUMIGAN 0.3 mg/ml, eye drops, solution, in single-dose container Bimatoprost

PATIENT INFORMATION LEAFLET. PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM RELESTAT, epinastine hydrochloride 0,5 mg/ml, eye drops

PATIENT INFORMATION LEAFLET

PATIENT INFORMATION LEAFLET

PACKAGE LEAFLET: INFORMATION FOR THE USER ACULAR 0.5% w/v EYE DROPS, SOLUTION (Ketorolac trometamol)

LUMIGAN EYE DROPS (bimatoprost 0.3 mg per ml)

PATIENT INFORMATION LEAFLET. PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM OZURDEX, dexamethasone 700 μg intravitreal implant

PRED FORTE 1% w/v Eye Drops, Suspension Prednisolone acetate

Package leaflet: Information for the user. GANFORT 0.3 mg/ml + 5 mg/ml eye drops, solution Bimatoprost/timolol

Package leaflet: Information for the user. PRED MILD STERILE OPHTHALMIC SUSPENSION 0.12% w/v Eye Drops, Suspension Prednisolone Acetate

Package leaflet: Information for the user. Relestat, 0.5 mg/ml, eye drops, solution Epinastine hydrochloride

Package leaflet: Information for the user. GANFORT 0.3 mg/ml + 5 mg/ml eye drops, solution, in single-dose container Bimatoprost/timolol

Dorzolamide 20 mg/ml Eye Drops, Solution

Pilocarpine 2% w/v Eye Drops, solution. Pilocarpine 4% w/v Eye Drops, solution. Pilocarpine Hydrochloride

APO-Latanoprost Contains the active ingredient latanoprost

Package leaflet: Information for the user. NEVANAC 1 mg/ml eye drops, suspension Nepafenac

Package leaflet: Information for the patient. Brimonidine Biogaran 2 mg/ml eye drops, solution. brimonidine tartrate

APO-Olopatadine Eye Drops Contains the active ingredient olopatadine (as olopatadine hydrochloride)

Package leaflet: Information for the user Oftaquix 5 mg/ml eye drops, solution. Levofloxacin

Package leaflet: Information for the user. Xalatan 50 micrograms/ml Eye drops, solution Latanoprost

BrinzoQuin Eye Drops 1.0%

ZADITEN Eye Drops 1.0%

Package leaflet: Information for the user. Carmellose sodium

PATIENT INFORMATION LEAFLET

Package Leaflet: Information for the user. NEVANAC 3 mg/ml eye drops, suspension nepafenac

Package leaflet: Information for the patient. IKERVIS 1 mg/ml, eye drops, emulsion ciclosporin

Package leaflet: Information for the user. Latanoprost Pfizer 50 micrograms/ml Eye drops, solution Latanoprost

PATIENT INFORMATION LEAFLET FOR TEXA 10 mg TABLETS AND TEXA SYRUP PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM:

NEVANAC TM 0.1% Eye Drops

ALPHAGAN EYE DROPS BRIMONIDINE TARTRATE

Read this entire leaflet carefully before you start taking DYNA BEZAFIBRATE. If you have further questions, please ask your doctor or your pharmacist.

TIMALEN 0.5% eye drops

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. XIIDRA TM* Lifitegrast Ophthalmic Solution 5%

TOBREX TM EYE DROPS and EYE OINTMENT 0.3%

Package leaflet: Information for the user. <product name> 3 mg/ml eye drops, solution. Ofloxacin

ACULAR EYE DROPS 5 mg/ml Eye Drops

PATIENT INFORMATION LEAFLET TEXAMER

Package Leaflet - Information for the User. TOBRADEX 3 mg/ml/1 mg/ml Eye Drops, Suspension Tobramycin and Dexamethasone

Package leaflet: Information for the patient. Verkazia 1 mg/ml eye drops emulsion ciclosporin

POLLENTYME S and Tabs Pharma Dynamics (Pty) Ltd Version: July 2017 (G1639) Word copy of G1639 PATIENT INFORMATION LEAFLET FOR POLLENTYME S AND TABS

MURINE HAYFEVER RELIEF 2% W/V EYE DROPS Sodium Cromoglicate

This indication includes the temporary relief of burning, irritation, and/or discomfort due to dryness of the eye.

PATIENT INFORMATION LEAFLET SIMVACOR RANGE

PATIENT INFORMATION LEAFLET POLLENTYME S AND TABS

MAXIDEX Eye Drops 0.1%

What Maxitrol Eye Drops is used for

It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist.

PATIENT INFORMATION LEAFLET PEPLOC RANGE

TRAVATAN Eye Drops 0.004% travoprost

PATIENT INFORMATION LEAFLET ZOXADON TABLETS RANGE

TOBRADEX TM Eye Drops

SCHEDULING STATUS Schedule 4 PROPRIETARY NAME AND DOSAGE FORM

PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: Read this entire leaflet carefully before you start taking DYNAFLOC.

PATIENT INFORMATION LEAFLET

CILOXAN TM Eye Drops 0.3%

PATIENT INFORMATION LEAFLET: Lancap 15 mg and 30 mg. Please read this leaflet carefully before taking LANCAP capsules.

DUOTRAV Eye Drops travoprost 0.004% and timolol 0.5%

TENOPT timolol maleate

Package leaflet: Information for the patient BETAXOLOL 0.5% EYE DROPS. Betaxolol (as hydrochloride)

DUOTRAV Eye Drops travoprost 0.004% and timolol 0.5% Consumer Medicine Information

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. IOPIDINE 1% Apraclonidine Ophthalmic Solution, USP

ENIDIN EYE DROPS [brimonidine tartrate]

VOLTAREN OPHTHA Eye Drops 0.1%

Before prescribing DUOTRAV Eye Drops for you, your doctor will have examined the eye and decided that DUOTRAV Eye Drops is the right medicine.

Package leaflet: Information for the patient. Xemacort 20 mg/g + 1 mg/g cream (fusidic acid and betamethasone)

Package leaflet: Information for the user

CIPROXIN HC Ear Drops

Package leaflet: Information for the user. Catacrom 2 % w/v Eye Drops, Solution. Sodium cromoglicate

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. T-LO Timolol Ophthalmic Solution (0.25%, 0.

PATIENT INFORMATION LEAFLET AMLOC RANGE

PATIENT INFORMATION LEAFLET DYNARB RANGE

Package leaflet: Information for the patient. Latanoprost 50 micrograms/ml eye drops, solution latanoprost

ILUVIEN 190 micrograms intravitreal implant in applicator (fluocinolone acetonide)

CONSUMER INFORMATION. Sandoz Travoprost / Timolol PQ ophthalmic solution travoprost and timolol ophthalmic solution with POLYQUAD * as preservative

ISOPTO CARPINE Eye Drops

Package leaflet: information for the user. OZURDEX 700 micrograms intravitreal implant in applicator dexamethasone

CONSUMER MEDICINE INFORMATION

MAXIDEX TM Eye Ointment 0.1%

MAXITROL Eye Ointment

Do not use Allergo-COMOD eye drops - if you are hypersensitive against sodium cromoglicate (Ph. Eur.) or one of the other ingredients.

IOPIDINE 5mg/ml Eye Drops, solution contain apraclonidine (as hydrochloride) as the active substance.

PATIENT INFORMATION LEAFLET EFFERFLU C IMMUNE BOOSTER. EFFERFLU C IMMUNE BOOSTER has not been evaluated by the Medicines Control

AZOPT EYE DROPS 1% What is in this leaflet. Before you use Azopt. What Azopt is used for. Brinzolamide. Consumer Medicine Information.

PRESCRIBING INFORMATION

INDICATIONS ACULAR 0,5 % is indicated for the relief of inflammation following ocular surgery.

PATIENT INFORMATION LEAFLET CARZIN XL

Proposed PIL NL/H/0653/001/IB/024/G. MONOFREE DEXAMETHASON 1 mg/ml, eye drops, solution in single-dose container Dexamethasone phosphate

Package leaflet: Information for the user. Bupivacaine 0.25% w/v, 0.5% w/v solution for injection Bupivacaine Hydrochloride

2 What you need to know before you use Beconase. Package Leaflet: Information for the user

PATIENT INFORMATION LEAFLET DYNAFIL RANGE

Zovirax Ophthalmic (eye) Ointment Acyclovir

PACKAGE LEAFLET: INFORMATION FOR THE USER ToboDexin 3 mg/g+1 mg/g eye ointment Tobramycin + Dexamethasone

Cutivate 0.05% w/w Cream fluticasone propionate

Package leaflet: Information for the user XATABLOC. 50 micrograms/ml + 5 mg/ml eye drops, solution latanoprost / timolol

INDICATIONS ACULAR 0,4% ophthalmic solution is indicated for the reduction of ocular pain and burning/stinging following corneal refractive surgery.

PHARMA DYNAMICS CLOPIDOGREL 75 mg PATIENT INFORMATION LEAFLET

PATIENT INFORMATION LEAFLET FOR FEDALOC 30 mg / 60 mg SR TABLETS. Please read this leaflet carefully before you start taking FEDALOC tablets.

Transcription:

Page 1 of 6 PATIENT INFORMATION LEAFLET SCHEDULING STATUS Schedule 4 Proprietary name, Strength and Pharmaceutical Form LUMIGAN 0,03 % Eye Drops (each ml contains bimatoprost 0,3 mg) Read all of this leaflet carefully before using LUMIGAN 0,03 % Keep this leaflet. You may need to read it again. If you have further questions, please ask your doctor or your pharmacist. LUMIGAN 0,03 % has been prescribed for you personally and you should not share your medicine with other people. It may harm them, even if their symptoms are the same as yours. 1. WHAT LUMIGAN 0,03 % CONTAINS The active substance is: Bimatoprost The other ingredients are: Benzalkonium chloride 0,005 % m/v (a preservative), sodium chloride, sodium phosphate dibasic heptahydrate, citric acid monohydrate and purified water. 2. WHAT LUMIGAN 0,03 % IS USED FOR LUMIGAN 0,03 % is prescribed to control glaucoma, which is high pressure in the eye. Bimatoprost belongs to a group of medicines called prostamides. LUMIGAN 0,03 % works by increasing the amount of liquid that is drained. This reduces the pressure inside the eye. LUMIGAN 0,03 % may be used on its own or with other drops called beta-blockers which also reduce pressure. 3. BEFORE YOU USE LUMIGAN 0,03 % Do not use LUMIGAN 0,03 % If you are hypersensitive (allergic) to bimatoprost or any of the other ingredients of LUMIGAN 0,03 %. Take special care with LUMIGAN 0,03 % Before you use this medicine, tell your doctor: If you have any breathing problems; If you have or have had low blood pressure or low heart rate;

Page 2 of 6 If you have liver or kidney problems; If you have had cataract surgery in the past; If you have or have had any problems with your cornea (front transparent part of the eye); If you have had a viral infection, inflammation of the eye or any other eye condition; If you are already using a medicine for glaucoma; If you wear contact lenses (see Important information about some of the ingredients of LUMIGAN 0,03 % ). LUMIGAN 0,03 % may cause your eyelashes to darken and grow, and cause the skin around the eyelid to darken too. The colour of your iris may also go darker over time. These changes may be permanent. The change may be more noticeable if you are only treating one eye. Hair may grow in areas where LUMIGAN 0,03 % solution has been repeatedly in contact with the skin surface. This is why it is important to apply LUMIGAN 0,03 % as instructed and to avoid it running onto the cheek or other skin areas. LUMIGAN 0,03 % should not be used in people under 18. Pregnancy and breastfeeding Always tell your healthcare provider if you are taking any other medicine. If you are pregnant or breastfeeding your baby, please consult your doctor, pharmacist or other healthcare professional for advice before using LUMIGAN 0,03 %. The safety of LUMIGAN 0,03 % in pregnancy has not been established. LUMIGAN 0,03 % should not be used during pregnancy unless your doctor still recommends it. LUMIGAN 0,03 % should not be used if you are breastfeeding because LUMIGAN 0,03 % may get into breast milk. Driving and using machinery Your sight may become blurred for a short time just after using LUMIGAN 0,03 %. You should not drive or use machines until your sight is clear again. Important information about some of the ingredients of LUMIGAN 0,03 % Contact lenses should be removed prior to using LUMIGAN 0,03 % in the eyes and may be reinserted 15 minutes following use of the eye drops. LUMIGAN 0,03 % should not be administered while wearing contact lenses. A preservative in LUMIGAN 0,03 % called benzalkonium chloride may cause eye irritation and can discolour soft contact lenses.

Page 3 of 6 Using other medicines with LUMIGAN 0,03 % Always tell your healthcare professional if you are taking any other medicines. (This includes complementary or traditional medicines.) If you use LUMIGAN 0,03 % with another eye medicine, leave at least 5 minutes between putting in LUMIGAN 0,03 % and the other medicine. 4. HOW TO USE LUMIGAN 0,03 % Do not share medicines prescribed for you with any other person. Always use LUMIGAN 0,03 % exactly as your doctor has instructed you. You should check with your doctor or pharmacist if you are unsure. If you have the impression that the effect of LUMIGAN 0,03 % is too strong or too weak, tell your doctor or pharmacist. LUMIGAN 0,03 % should only be applied to the eye. The usual dose is one drop in each eye that needs treatment, once every day, in the evening, following the instructions for use below. Instructions for use 1. Wash your hands. Tilt your head back and look at the ceiling. 2. Gently pull down the lower eyelid until there is a small pocket. 3. Turn the bottle upside down and squeeze it to release one drop into each eye that needs treatment. 4. Let go of the lower lid, and close your eye for 30 seconds. If a drop misses your eye, try again. Wipe off any excess that runs down the cheek. To help prevent infections, do not let the tip of the bottle touch your eye or anything else. Put the cap back on and close the bottle straight after you have used it. If you use more LUMIGAN 0,03 % than you should If you use more LUMIGAN 0,03 % than you should, it is unlikely to cause you any serious harm. Put your next dose in at the usual time. If you are worried, talk to your doctor or pharmacist.

Page 4 of 6 In the event of overdosage, consult your doctor or pharmacist. If neither is available, contact the nearest hospital or poison control centre. If you forget to use LUMIGAN 0,03 % Use a single drop as soon as you remember, and then go back to your regular routine. Do not use a double dose to make up for a forgotten dose. If you have trouble remembering when to use your medicine, ask your pharmacist for some hints. Effects when treatment with LUMIGAN 0,03 % is stopped LUMIGAN 0,03 % should be used every day to work properly. 5. POSSIBLE SIDE EFFECTS LUMIGAN 0,03 % can have side effects. Not all side effects reported for LUMIGAN 0,03 % are included in this leaflet. Should your general health worsen, or if you experience any untoward effects while using LUMIGAN 0,03 %, please consult your healthcare provider for advice. Frequent side effects Affecting the eye: Longer eyelashes Redness Itchiness An allergic reaction in the eye Tired eyes Sensitivity to light Darker skin colour around the eye Darker eyelashes Pain A feeling that something is in your eye Sticky eyes Darker iris colour Difficulty in seeing clearly Worsening of vision Blurred vision Irritation Burning Inflamed, red and itchy eyelids Tears

Page 5 of 6 Dryness Swelling of the see-through layer which covers the surface of the eye Cataract Small breaks in the surface of the eye, with or without inflammation Affecting the body: Abnormal liver function tests Less frequent side effects Affecting the eye: Inflammation within the eye Retinal bleeding Eyelid twitching Affecting the body: Hair growth around the eye Weakness Swelling in the arms and/or legs Colds Side effects where the frequency is not known Affecting the eye: Eyelid shrinking, moving away from the surface of the eye Eyes appear sunken Skin redness around the eye Swollen eyelid Macular oedema (swelling of the retina within the eye leading to worsening vision) Affecting the body Abnormal hair growth Nausea Symptoms of allergic reaction (swelling, redness of the eye and rash of the skin) Dizziness Headaches Asthma Worsening of asthma Shortness of breath Increased blood pressure If you notice any side effects not mentioned in this leaflet, please inform your doctor or

Page 6 of 6 pharmacist. 6. STORING AND DISPOSING OF LUMIGAN 0,03 % Store at or below 25 C. Store all medicines out of reach of children. Once opened, solutions may become contaminated, which can cause eye infections. Therefore, you must throw away the bottle 4 weeks (28 days) after you first opened it, even if some solution is left. To help you remember, write down the date that you opened it in the space on the carton. Do not use the eye drops after the expiry date printed on the carton and bottle. Keep bottle tightly closed when you are not using it to prevent contamination. Return all unused medicine to your pharmacist. Do not dispose of unused medicine in drains and sewerage systems (e.g. toilets). 7. PRESENTATION OF LUMIGAN 0,03 % 3 ml solution filled into a white opaque low density polyethylene bottle with a polystyrene screw cap. Each bottle is packed into an outer carton. 8. IDENTIFICATION OF LUMIGAN 0,03 % Clear colourless to slightly yellow solution with no foreign particles. 9. REGISTRATION NUMBER 36/15.4/0157 10. NAME AND ADDRESS OF REGISTRATION HOLDER 30 New Road (entrance off Bavaria Road) Randjespark Ext 11, Midrand, 1682 Johannesburg, Gauteng South Africa Tel. 011 545 6600 11. DATE OF PUBLICATION Date of registration: 7 March 2003 Date of the most recently revised Patient Information Leaflet as approved by the Authority: 21 June 2013 Professional Information can be accessed via http://www.allergan.co.za/en-za/products In case of an adverse event, please contact +27 11 545 6600 or send an email to SA_Complaints@Allergan.com